☆ 4.6 Article

Assessment of bleeding risk in cancer patients treated with anticoagulants for venous thromboembolic events

FRONTIERS IN CARDIOVASCULAR MEDICINE (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Hematology

Estimating Bleeding Risk in Patients with Cancer-Associated Thrombosis: Evaluation of Existing Risk Scores and Development of a New Risk Score

Maria A. de Winter et al.

Summary: The study compared different methods of estimating clinically relevant bleeding risk in patients with CAT, finding that existing risk scores performed poorly while a pragmatic classification based on cancer type provided slightly better estimates. Further improvement may be possible with a new prediction model, but external validation is needed.

THROMBOSIS AND HAEMOSTASIS (2022)

添加到收藏夹

Review Oncology

In Search of the Appropriate Anticoagulant-Associated Bleeding Risk Assessment Model for Cancer-Associated Thrombosis Patients

Geraldine Poenou et al.

Summary: Patients with cancer-associated venous thromboembolism should receive anticoagulant treatment as long as cancer is active, requiring an individualized risk assessment model. Current risk assessment models have limitations, and there is a need for further research to develop a new model for assessing bleeding risk in cancer-associated thrombosis patients.

CANCERS (2022)

添加到收藏夹

Review Pharmacology & Pharmacy

Drug-Drug Interactions of Direct Oral Anticoagulants (DOACs): From Pharmacological to Clinical Practice

Nicola Ferri et al.

Summary: Direct oral anticoagulants (DOACs) are frequently prescribed to prevent ischemic stroke in non-valvular atrial fibrillation (NVAF) patients and treat venous thromboembolism (VTE). They have a favorable risk-benefit profile compared to warfarin but may increase the risk of gastrointestinal bleeding. Polypharmacy and comorbidity in elderly patients can lead to drug-drug interactions (DDIs) with DOACs. This review summarizes potential DDIs and discusses strategies to reduce their occurrence.

PHARMACEUTICS (2022)

添加到收藏夹

Article Hematology

Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study

Walter Ageno et al.

Summary: The Caravaggio study showed that apixaban is a safe alternative to LMWH for the treatment of CAT patients, without an increased risk of gastrointestinal bleeding.

THROMBOSIS AND HAEMOSTASIS (2021)

添加到收藏夹

Review Hematology

Prediction models for recurrence and bleeding in patients with venous thromboembolism: A systematic review and critical appraisal

Maria A. de Winter et al.

Summary: Prediction models for VTE recurrence and anticoagulation-related bleeding often exhibit poor performance in external validation studies, with significant methodological limitations that undermine their utility in clinical practice.

THROMBOSIS RESEARCH (2021)

添加到收藏夹

Article Hematology

American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer

Gary H. Lyman et al.

Summary: These evidence-based guidelines aim to support decision-making on the prevention and treatment of VTE in cancer patients, covering mechanical and pharmacological prophylaxis, as well as recommendations for initial, short-term, and long-term treatment based on patient risk and treatment circumstances. Recommendations vary depending on patient risk level and treatment situation.

BLOOD ADVANCES (2021)

添加到收藏夹

Article Critical Care Medicine

An Original Risk Score to Predict Early Major Bleeding in Acute Pulmonary Embolism The Syncope, Anemia, Renal Dysfunction (PE-SARD) Bleeding Score

Romain Chopard et al.

Summary: A risk score, PE-SARD, was developed to predict early major bleeding in acute PE patients. Three predictors - Syncope, Anemia, and Renal Dysfunction - were identified. The novel score showed better performance than existing models, allowing for accurate risk classification and reclassification.

CHEST (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Claims-Based Score for the Prediction of Bleeding in a Contemporary Cohort of Patients Receiving Oral Anticoagulation for Venous Thromboembolism

Alvaro Alonso et al.

Summary: A novel bleeding prediction model for VTE patients using large healthcare claims databases was developed, showing moderately good performance and emphasizing the urgent need for better predictors to inform treatment decisions.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2021)

添加到收藏夹

Article Hematology

Prediction of significant bleeding during vitamin K antagonist treatment for venous thromboembolism in outpatients

Carlos Martinez et al.

BRITISH JOURNAL OF HAEMATOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

D-dimer levels enhance the discriminatory capacity of bleeding risk scores for predicting in-hospital bleeding events in acute pulmonary embolism

Marta Skowronska et al.

EUROPEAN JOURNAL OF INTERNAL MEDICINE (2019)

添加到收藏夹

Article Hematology

Derivation and validation of a novel bleeding risk score for elderly patients with venous thromboembolism on extended anticoagulation

E. Seiler et al.

THROMBOSIS AND HAEMOSTASIS (2017)

添加到收藏夹

Article Hematology

Prediction of major and clinically relevant bleeding in patients with VTE treated with edoxaban or vitamin K antagonists

Marcello Di Nisio et al.

THROMBOSIS AND HAEMOSTASIS (2017)

添加到收藏夹

Article Critical Care Medicine

Antithrombotic Therapy for VTE Disease CHEST Guideline and Expert Panel Report

Clive Kearon et al.

CHEST (2016)

添加到收藏夹

Article Respiratory System

Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment

Frederikus A. Klok et al.

EUROPEAN RESPIRATORY JOURNAL (2016)

添加到收藏夹

Article Hematology

Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists

Marcello Di Nisio et al.

THROMBOSIS AND HAEMOSTASIS (2016)

添加到收藏夹

Article Oncology

Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD statement

G. S. Collins et al.

BRITISH JOURNAL OF CANCER (2015)

添加到收藏夹

Article Hematology

Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH

S. Kaatz et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2015)

添加到收藏夹

Article Hematology

Validation of a score for predicting fatal bleeding in patients receiving anticoagulation for venous thromboembolism

Jose Antonio Nieto et al.

THROMBOSIS RESEARCH (2013)

添加到收藏夹

Article Hematology

Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism.: Findings from the RIETE Registry

Nuria Ruiz-Gimenez et al.

THROMBOSIS AND HAEMOSTASIS (2008)

添加到收藏夹

Article Hematology

Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients

S Schulman et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)

添加到收藏夹

Review Hematology

Management of thrombosis in cancer: primary prevention and secondary prophylaxis

AYY Lee

BRITISH JOURNAL OF HAEMATOLOGY (2005)

添加到收藏夹

Article Hematology

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis

P Prandoni et al.

BLOOD (2002)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.